Posted: August 14, 2024 at 2:37 am
LONG BEACH, Calif. and TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today reported financial results for the second quarter ended June 30, 2024.
Here is the original post:
Glass House Brands Reports Record Setting Second Quarter 2024 Financial Results
Posted: August 14, 2024 at 2:37 am
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults
Continue reading here:
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Posted: August 14, 2024 at 2:37 am
AI Technology to Assist Clinicians to Drive Better Outcomes in Brain Health AI Technology to Assist Clinicians to Drive Better Outcomes in Brain Health
Read this article:
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
Posted: August 14, 2024 at 2:37 am
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 -
Visit link:
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Posted: August 14, 2024 at 2:37 am
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.
Visit link:
Panbela Provides Business Update and Reports Q2 2024 Financial Results
Posted: August 14, 2024 at 2:37 am
COPENHAGEN, Denmark, August 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today a new order from HERA (the European Health Emergency Preparedness and Response Authority) for the Company’s MVA-BN® vaccine, the only FDA and EMA-approved mpox vaccine. HERA will procure 175,420 doses of the vaccine for donation to the Africa CDC (Centres for Disease Control and Prevention) in support of their strengthened response to the mpox outbreak which is spreading across the African continent. Additionally, Bavarian Nordic will donate 40,000 doses to HERA, also to be donated to the Africa CDC.
Read the rest here:
Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa
Posted: August 14, 2024 at 2:37 am
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline.
View post:
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Posted: August 14, 2024 at 2:37 am
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.
See the original post here:
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
Posted: August 14, 2024 at 2:37 am
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 -
View original post here:
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Posted: August 14, 2024 at 2:37 am
• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death• AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T cells• Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings• AMPLIFY-7P Phase 2 randomized clinical trial anticipated to complete 135-patient enrollment in the fourth quarter of 2024• $43 million raised in 2024 funds Elicio into the second quarter of 2025
Link:
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
